Merck & Co., Inc. (MRK) yesterday, won the US Food and Drug Administration’s (FDA) Accelerated Approval for its breakthrough cancer therapy, Keytruda. It beat Bristol-Myers Squibb Co. (BMY) by becoming the first company first to get approval for a PD-1 inhibitor drug in the US. Keytruda has been approved for the treatment of advanced melanoma in patients who have failed treatments with Bristol-Myers’ Yervoy and other drugs.
Bristol-Myers Squibb Co (NYSE:BMY) and Merck & Co., Inc.’s (NYSE:MRK) respective cancer immunotherapies, Opdivo and Keytruda, showed promising results for the treatment of Hodgkin’s lymphoma in two separate studies, researchers announced Saturday.
Eli Lilly and Co (NYSE:LLY) announced two separate collaborations, one with Merck & Co., Inc. (NSYE:MRK), and the other with Bristol-Myers Squibb Co (NYSE:BMY), to conduct the clinical tests of cancer drugs developed by both companies.
By Peter Geschek:Even with the best cancer drugs, doctors are forced to switch from one therapy to the next as the tumors rapidly develop resistance.A new wave of immunotherapy drugs, in the spotlight of the upcoming ASCO (American Society of Clinical Oncology) meeting, promises to produce longer-lasting remissions.
WASHINGTON (AP) — Federal health officials on Tuesday approved a first-of-a-kind drug that uses the herpes virus to infiltrate and destroy deadly skin cancer tumors.The Food and Drug Administration approved the injectable drug from Amgen Inc. for patients with hard-to-treat melanoma, the deadliest form of skin cancer that is expected to be diagnosed in 74,000 U.S. patients this year. For now, the drug is only approved for melanoma tumors that cannot be removed surgically.
Merck & Co., Inc. (NYSE:MRK) may have struck a winning shot against Bristol-Meyrs Squibb Co (NYSE:BMY) in immune-oncology on Friday. The Food and Drug Administration (FDA) expanded its approval of Merck\'s anti-PD-1 drug Keytruda to include front-line treatment of unresectable or metastatic melanoma.
Merck & Co., Inc. (NYSE:MRK), the second-largest US drug-maker by revenue, is fast becoming a reckoning force in the market of immunotherapy cancer drugs. However, the drug-maker still trails pharmaceutical giant Bristol-Myers Squibb Co, which currently dominates the immunotherapy market.
Merck & Co., Inc. (NYSE:MRK), the second-largest US drug maker, has announced a collaboration agreement with the Japanese pharmaceutical company Eisai Co., Ltd (ADR) (OTCMKTS:ESALY). They will carry out multiple clinical trials to analyze the safety and efficacy of Merck’s KEYTRUDA in combination with Eisai’s cancer compounds, including LENVIMA and HALAVEN.